European Association of Urology and American Society of Clinical Oncology Guidelines on Penile Cancer: A Summary of the 2026 Guidelines Update

Updated international penile cancer guidelines lean heavily on retrospective data and expert consensus, not trials

Journal: European Urology | Published: 2026-04-27 | Type: Journal Article, Review, Practice Guideline | PMID: 42049595 Authors: Arie Parnham (The Christie NHS Foundation Trust, Manchester), Maarten Albersen (University Hospitals Leuven), Benjamin Ayres (St George's University Hospitals NHS Foundation Trust), Juanita Crook (University of British Columbia), Peter A.S. Johnstone (Moffitt Cancer Center), Pedro Oliveira (The Christie NHS Foundation Trust), Lance C. Pagliaro (Mayo Clinic), Curtis Pettaway (MD Anderson Cancer Center), Chris Protzel (Helios Clinics Schwerin), R. Bryan Rumble (American Society of Clinical Oncology) — a joint EAU-ASCO guideline panel Funding/COI: Not listed

Summary

This is not a clinical trial — it's a joint European Association of Urology/American Society of Clinical Oncology panel's summary of updated practice guidelines for penile cancer, a rare malignancy. The update revises pathological risk stratification, recommends routine ultrasound-guided lymph node assessment, expands the case for organ-preserving surgery, and adds selective genomic testing to the mix. The panel itself acknowledges that most of this rests on retrospective studies and expert consensus rather than randomized evidence, because the disease is too rare to generate much else.

Claims

• Pathological risk stratification for predicting nodal spread has been refined from prior versions.
• Ultrasound-guided assessment of regional lymph nodes is now recommended as routine practice rather than selective use.
• Broader criteria are proposed for organ-preserving surgical approaches instead of penectomy.
• Selective genomic testing is newly supported for a subset of patients.
• New flow diagrams restructure decision-making for nodal management.
• Systemic therapy recommendations are expanded, citing a larger evidence base than prior guideline versions.
• Follow-up schedules are streamlined ("rationalised") and care centralization is emphasized.

Study Quality

This is a guideline document, not a primary study, so it can't be scored the way a trial or cohort study would be. What can be assessed is the evidence base underpinning it, and the authors are unusually candid about its limits: they state outright that "many recommendations remain informed by retrospective data and expert consensus, reflecting the rarity of the disease and limited prospective evidence." That's an accurate characterization of penile cancer research generally — global incidence is low enough that multicenter RCTs are logistically difficult, and most management data comes from single-institution case series or multinational retrospective cohorts.

The methodology described — "structured literature assessment and expert panel consensus, incorporating evaluation of benefits and harms, evidence uncertainty and patient values" — is standard for guideline development (similar to GRADE-style frameworks), but the abstract doesn't specify which formal evidence-grading system was used, how disagreements among panelists were resolved, or what proportion of recommendations were graded as low- versus high-certainty evidence. Readers wanting to distinguish "recommend because two RCTs showed it" from "recommend because a panel of ten experts agreed" will need to consult the full guideline document, not this summary.

Red Flags

• No funding source or conflict-of-interest disclosure listed for the paper itself, despite penile cancer treatment recommendations touching on surgical devices, systemic therapy agents, and imaging protocols where industry ties are common in oncology guideline panels.
• The abstract doesn't quantify how much of the guideline is low-certainty evidence versus high-certainty — "many recommendations" is vague.
• No numbers anywhere in the abstract (sample sizes of underlying studies, effect sizes for organ-preserving surgery vs. penectomy, node positivity rates informing the ultrasound recommendation) — this is a summary of a summary, several steps removed from raw data.
• "Selective genomic testing" is endorsed without detail on which genomic markers, what evidence supports them, or what treatment decisions they're meant to inform.

Strengths

• Joint development between two major oncology/urology societies (EAU and ASCO) adds cross-continental clinical input, which matters for a disease with geographic variation in incidence and access to specialized surgical care.
• Explicit acknowledgment of evidence limitations rather than overselling consensus-based recommendations as high-certainty.
• Addresses survivorship and quality of life as guideline priorities, not just oncologic outcomes — notable for a cancer where treatment (partial or total penectomy, lymphadenectomy) carries major functional and psychological consequences.
• Emphasis on care centralization is consistent with outcomes literature showing better results at high-volume penile cancer centers.

Verdict

Useful as a snapshot of where specialist consensus currently sits on a rare cancer, and refreshingly honest that "consensus" is doing a lot of the work here — but this abstract is a summary of a guideline, not a study, and it contains zero numbers to independently evaluate. Worth reading if you want to know what changed in clinical practice recommendations; not a substitute for the underlying systematic reviews if you want to know how strong the evidence actually is.